Linezolid Use in Patients with Anemia

Hematologic Risk Profile

Pre-existing anemia is a major risk factor for developing severe linezolid-induced anemia, according to the American College of Physicians, as myelosuppression has been reported across all patient populations receiving linezolid 1

Linezolid may be necessary in patients with anemia when treating multidrug-resistant tuberculosis or serious Gram-positive infections, as the mortality benefit can outweigh hematologic risks, and strict clinical monitoring is mandatory, as recommended by the American Thoracic Society 2
Standard dosing (600 mg daily) is associated with fewer adverse events (46.7%) compared to higher doses (1200 mg daily: 74.5%) without compromising effectiveness, based on evidence from the Infectious Diseases Society of America 3
In tuberculosis treatment, over half of patients required dose reduction to 300 mg due to myelosuppression or neurotoxicity, as reported by the European Society of Clinical Microbiology and Infectious Diseases 4

Children <10 years of age are particularly susceptible to myelosuppression at standard dosing (10 mg/kg twice daily), according to the American Academy of Pediatrics 2
Children <10 years of age are also at increased risk of myelosuppression, as reported by the Pediatric Infectious Diseases Society, with a recommended dose adjustment to minimize this risk 3